Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.43)
# 4,231
Out of 5,124 analysts
16
Total ratings
28.57%
Success rate
-17.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.41 | +631.35% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $2.35 | +580.85% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $3.35 | +168.66% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.74 | +113.90% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $27.27 | +266.70% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.58 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.22 | +68,081.82% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $1.51 | +893.38% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $5.84 | +259.59% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $65.30 | +37.83% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.14 | +14,385.98% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $2.32 | +1,448,175.86% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.41
Upside: +631.35%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $2.35
Upside: +580.85%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $3.35
Upside: +168.66%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.74
Upside: +113.90%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $27.27
Upside: +266.70%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.58
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.22
Upside: +68,081.82%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $1.51
Upside: +893.38%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $5.84
Upside: +259.59%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $65.30
Upside: +37.83%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.14
Upside: +14,385.98%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $2.32
Upside: +1,448,175.86%